Segment Reporting (Details) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
|
Jun. 30, 2025
USD ($)
|
Mar. 31, 2025
USD ($)
|
Jun. 30, 2024
USD ($)
|
Mar. 31, 2024
USD ($)
|
Jun. 30, 2025
USD ($)
segment
|
Jun. 30, 2024
USD ($)
|
|
| Segment Reporting | ||||||
| Number of operating segments | segment | 1 | |||||
| Revenue | $ 13,459 | $ 16,441 | $ 24,156 | $ 31,215 | ||
| Cost of product revenue | 1,944 | 1,509 | 3,206 | 2,835 | ||
| Research & Development | ||||||
| Stock-based compensation | 9,678 | 11,293 | 20,134 | 19,271 | ||
| Depreciation | 2,007 | 1,876 | ||||
| Interest income | 3,455 | 6,036 | 7,282 | 9,958 | ||
| Interest expense | (3,016) | (3,196) | (6,000) | (7,247) | ||
| Loss from debt extinguishment | (27,950) | |||||
| Net Income (Loss) | (67,814) | $ (64,053) | (43,777) | $ (64,848) | (131,867) | (108,625) |
| Single Reportable Segment | ||||||
| Segment Reporting | ||||||
| Revenue | 13,459 | 16,441 | 24,156 | 31,215 | ||
| Cost of product revenue | 1,944 | 1,509 | 3,206 | 2,835 | ||
| Research & Development | ||||||
| Direct program expenses, AXPAXLI for wet AMD | 33,158 | 12,753 | 57,613 | 18,246 | ||
| Direct program expenses, Other clinical and preclinical programs | 1,001 | 2,351 | 2,081 | 5,566 | ||
| Unallocated expenses, Personnel costs | 9,350 | 7,489 | 18,689 | 14,617 | ||
| Unallocated expenses, All other costs | 2,039 | 1,654 | 4,925 | 2,451 | ||
| Selling and marketing | 12,477 | 9,147 | 25,251 | 18,396 | ||
| General and administrative | 8,649 | 11,140 | 18,301 | 19,463 | ||
| Facilities | 1,777 | 1,739 | 3,508 | 3,701 | ||
| Stock-based compensation | 9,678 | 11,293 | 20,134 | 19,271 | ||
| Depreciation | 1,027 | 956 | 2,007 | 1,876 | ||
| Interest income | 3,455 | 6,036 | 7,282 | 9,958 | ||
| Interest expense | (3,016) | (3,196) | (6,000) | (7,247) | ||
| Loss from debt extinguishment | (27,950) | |||||
| Other non-operating items | (612) | (3,027) | (1,590) | (8,179) | ||
| Net Income (Loss) | $ (67,814) | $ (43,777) | $ (131,867) | $ (108,625) | ||
| X | ||||||||||
- Definition Amount of expense for facilities. No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line, excluding stock-based compensation and depreciation. No definition available.
|
| X | ||||||||||
- Definition Net amount of income (expense) related to nonoperating items not separately disclosed. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development related to other clinical and preclinical programs. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development related to Retina Programs, AXPAXLI for wet AMD. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development related to unallocated expenses for all other costs. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development related to unallocated expenses for personnel costs. No definition available.
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services, excluding stock-based compensation and depreciation. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|